Cancer/Testis antigens as potential predictors of biochemical recurrence of prostate cancer following radical prostatectomy

Takumi Shiraishi, Naoki Terada, Yu Zeng, Takahito Suyama, Jun Luo, Bruce Trock, Prakash Kulkarni, Robert H. Getzenberg

Research output: Contribution to journalArticle

Abstract

Background: The Cancer/Testis Antigens (CTAs) are an important group of proteins that are typically restricted to the testis in the normal adult but are aberrantly expressed in several types of cancers. As a result of their restricted expression patterns, the CTAs could serve as unique biomarkers for cancer diagnosis/prognosis. The aim of this study was to identify promising CTAs that are associated with prostate cancer (PCa) recurrence following radical prostatectomy (RP).Methods: The expression of 5 CTAs was measured by quantitative multiplex real-time PCR using prostate tissue samples obtained from 72 patients with apparently clinically localized PCa with a median of two years follow-up (range, 1 to 14 years).Results: The expression of CTAs namely, CEP55, NUF2, PBK and TTK were significantly higher while PAGE4 was significantly lower in patients with recurrent disease. All CTAs with the exception of TTK were significantly correlated with the prostatectomy Gleason score, but none were correlated with age, stage, or preoperative PSA levels. In univariate proportional hazards models, CEP55 (HR = 3.59, 95% CI: 1.50-8.60), p = 0.004; NUF2 (HR = 2.28, 95% CI: 1.11-4.67), p = 0.024; and PAGE4 (HR = 0.44, 95% CI: 0.21-0.93), p = 0.031 were significantly associated with the risk of PCa recurrence. However, the results were no longer significant after adjustment for prostatectomy Gleason score.Conclusions: To our knowledge, this is the first study to identify CTAs as biomarkers that can differentiate patients with recurrent and non-recurrent disease following RP and underscores its potential impact on PCa prognosis and treatment.

Original languageEnglish (US)
Article number153
JournalJournal of Translational Medicine
Volume9
Issue number1
DOIs
StatePublished - Sep 14 2011

Fingerprint

Testicular Neoplasms
Prostatectomy
Prostatic Neoplasms
Antigens
Recurrence
Neoplasm Grading
Multiplex Polymerase Chain Reaction
Biomarkers
Tumor Biomarkers
Proportional Hazards Models
Testis
Real-Time Polymerase Chain Reaction
Prostate
Hazards
Tissue
Neoplasms
Proteins

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)
  • Medicine(all)

Cite this

Cancer/Testis antigens as potential predictors of biochemical recurrence of prostate cancer following radical prostatectomy. / Shiraishi, Takumi; Terada, Naoki; Zeng, Yu; Suyama, Takahito; Luo, Jun; Trock, Bruce; Kulkarni, Prakash; Getzenberg, Robert H.

In: Journal of Translational Medicine, Vol. 9, No. 1, 153, 14.09.2011.

Research output: Contribution to journalArticle

Shiraishi, Takumi ; Terada, Naoki ; Zeng, Yu ; Suyama, Takahito ; Luo, Jun ; Trock, Bruce ; Kulkarni, Prakash ; Getzenberg, Robert H. / Cancer/Testis antigens as potential predictors of biochemical recurrence of prostate cancer following radical prostatectomy. In: Journal of Translational Medicine. 2011 ; Vol. 9, No. 1.
@article{550bb34a06bb46f9ad4eb23d0af6c7fe,
title = "Cancer/Testis antigens as potential predictors of biochemical recurrence of prostate cancer following radical prostatectomy",
abstract = "Background: The Cancer/Testis Antigens (CTAs) are an important group of proteins that are typically restricted to the testis in the normal adult but are aberrantly expressed in several types of cancers. As a result of their restricted expression patterns, the CTAs could serve as unique biomarkers for cancer diagnosis/prognosis. The aim of this study was to identify promising CTAs that are associated with prostate cancer (PCa) recurrence following radical prostatectomy (RP).Methods: The expression of 5 CTAs was measured by quantitative multiplex real-time PCR using prostate tissue samples obtained from 72 patients with apparently clinically localized PCa with a median of two years follow-up (range, 1 to 14 years).Results: The expression of CTAs namely, CEP55, NUF2, PBK and TTK were significantly higher while PAGE4 was significantly lower in patients with recurrent disease. All CTAs with the exception of TTK were significantly correlated with the prostatectomy Gleason score, but none were correlated with age, stage, or preoperative PSA levels. In univariate proportional hazards models, CEP55 (HR = 3.59, 95{\%} CI: 1.50-8.60), p = 0.004; NUF2 (HR = 2.28, 95{\%} CI: 1.11-4.67), p = 0.024; and PAGE4 (HR = 0.44, 95{\%} CI: 0.21-0.93), p = 0.031 were significantly associated with the risk of PCa recurrence. However, the results were no longer significant after adjustment for prostatectomy Gleason score.Conclusions: To our knowledge, this is the first study to identify CTAs as biomarkers that can differentiate patients with recurrent and non-recurrent disease following RP and underscores its potential impact on PCa prognosis and treatment.",
author = "Takumi Shiraishi and Naoki Terada and Yu Zeng and Takahito Suyama and Jun Luo and Bruce Trock and Prakash Kulkarni and Getzenberg, {Robert H.}",
year = "2011",
month = "9",
day = "14",
doi = "10.1186/1479-5876-9-153",
language = "English (US)",
volume = "9",
journal = "Journal of Translational Medicine",
issn = "1479-5876",
publisher = "BioMed Central",
number = "1",

}

TY - JOUR

T1 - Cancer/Testis antigens as potential predictors of biochemical recurrence of prostate cancer following radical prostatectomy

AU - Shiraishi, Takumi

AU - Terada, Naoki

AU - Zeng, Yu

AU - Suyama, Takahito

AU - Luo, Jun

AU - Trock, Bruce

AU - Kulkarni, Prakash

AU - Getzenberg, Robert H.

PY - 2011/9/14

Y1 - 2011/9/14

N2 - Background: The Cancer/Testis Antigens (CTAs) are an important group of proteins that are typically restricted to the testis in the normal adult but are aberrantly expressed in several types of cancers. As a result of their restricted expression patterns, the CTAs could serve as unique biomarkers for cancer diagnosis/prognosis. The aim of this study was to identify promising CTAs that are associated with prostate cancer (PCa) recurrence following radical prostatectomy (RP).Methods: The expression of 5 CTAs was measured by quantitative multiplex real-time PCR using prostate tissue samples obtained from 72 patients with apparently clinically localized PCa with a median of two years follow-up (range, 1 to 14 years).Results: The expression of CTAs namely, CEP55, NUF2, PBK and TTK were significantly higher while PAGE4 was significantly lower in patients with recurrent disease. All CTAs with the exception of TTK were significantly correlated with the prostatectomy Gleason score, but none were correlated with age, stage, or preoperative PSA levels. In univariate proportional hazards models, CEP55 (HR = 3.59, 95% CI: 1.50-8.60), p = 0.004; NUF2 (HR = 2.28, 95% CI: 1.11-4.67), p = 0.024; and PAGE4 (HR = 0.44, 95% CI: 0.21-0.93), p = 0.031 were significantly associated with the risk of PCa recurrence. However, the results were no longer significant after adjustment for prostatectomy Gleason score.Conclusions: To our knowledge, this is the first study to identify CTAs as biomarkers that can differentiate patients with recurrent and non-recurrent disease following RP and underscores its potential impact on PCa prognosis and treatment.

AB - Background: The Cancer/Testis Antigens (CTAs) are an important group of proteins that are typically restricted to the testis in the normal adult but are aberrantly expressed in several types of cancers. As a result of their restricted expression patterns, the CTAs could serve as unique biomarkers for cancer diagnosis/prognosis. The aim of this study was to identify promising CTAs that are associated with prostate cancer (PCa) recurrence following radical prostatectomy (RP).Methods: The expression of 5 CTAs was measured by quantitative multiplex real-time PCR using prostate tissue samples obtained from 72 patients with apparently clinically localized PCa with a median of two years follow-up (range, 1 to 14 years).Results: The expression of CTAs namely, CEP55, NUF2, PBK and TTK were significantly higher while PAGE4 was significantly lower in patients with recurrent disease. All CTAs with the exception of TTK were significantly correlated with the prostatectomy Gleason score, but none were correlated with age, stage, or preoperative PSA levels. In univariate proportional hazards models, CEP55 (HR = 3.59, 95% CI: 1.50-8.60), p = 0.004; NUF2 (HR = 2.28, 95% CI: 1.11-4.67), p = 0.024; and PAGE4 (HR = 0.44, 95% CI: 0.21-0.93), p = 0.031 were significantly associated with the risk of PCa recurrence. However, the results were no longer significant after adjustment for prostatectomy Gleason score.Conclusions: To our knowledge, this is the first study to identify CTAs as biomarkers that can differentiate patients with recurrent and non-recurrent disease following RP and underscores its potential impact on PCa prognosis and treatment.

UR - http://www.scopus.com/inward/record.url?scp=80052822970&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80052822970&partnerID=8YFLogxK

U2 - 10.1186/1479-5876-9-153

DO - 10.1186/1479-5876-9-153

M3 - Article

C2 - 21917134

AN - SCOPUS:80052822970

VL - 9

JO - Journal of Translational Medicine

JF - Journal of Translational Medicine

SN - 1479-5876

IS - 1

M1 - 153

ER -